Viatris stock unchanged as Goldman maintains Neutral rating on trial miss

Viatris Inc. (VTRS) maintained a Neutral rating and $10 price target from Goldman Sachs despite the failure of its Phase 3 trial for MR-139, an eye medication, to meet its primary endpoint. While considered an "incremental setback" to Viatris's branded pipeline, this drug was not in Goldman's financial models, and the company has reported positive Phase 3 results for other treatments, including MR-141 for presbyopia, with an FDA submission planned for H2 2025. However, Goldman Sachs also cited broader concerns, including structural challenges in Viatris's core business, modest generics growth, and an FDA warning letter impacting an Indian manufacturing site, projected to reduce 2025 revenue by approximately $500 million.

Analysis

Viatris Inc. (VTRS) presents a mixed investment profile characterized by pipeline setbacks, regulatory headwinds, and an attractive valuation. The company's Phase 3 trial failure for its blepharitis treatment, MR-139, is viewed by Goldman Sachs as an "incremental set-back" to its branded pipeline development, though it does not impact current financial models as the drug was not included in consensus estimates. Consequently, Goldman Sachs maintained its Neutral rating and $10.00 price target. This negative development is partially offset by positive Phase 3 results in other therapeutic areas, particularly the presbyopia treatment MR-141, for which Viatris plans an FDA submission in the second half of 2025. However, more significant challenges loom, including an FDA warning letter and import alert for a manufacturing site in India, which is expected to reduce 2025 revenue by a material $500 million. This specific financial impact compounds broader concerns cited by Goldman Sachs regarding structural dynamics in the company's core business and modest growth in its generics segment. Despite these operational and regulatory hurdles, the stock offers a substantial 5.18% dividend yield and is noted to appear undervalued, creating a classic tension between current shareholder returns and future growth uncertainty.

Key Decisions for Investors

• Investors should closely monitor the resolution of the FDA warning letter, as the projected $500 million revenue impact for 2025 represents a significant near-term risk to financial performance.
• The progress of the presbyopia treatment MR-141, including its planned FDA submission in H2 2025, should be tracked as a key potential catalyst that could offset recent pipeline disappointments and drive future branded growth.
• For income-oriented portfolios, the 5.18% dividend yield may warrant consideration, but this must be weighed against the company's modest growth profile and significant operational headwinds.